Jim Greenwood, Author at CDR – Chain Drug Review

Pharmacy Outlook: Jim Greenwood, Biotechnology Innovation Organization

January 12, 2020 by Jim Greenwood Biotechnology Innovation Organization, Jim Greenwood January 6, 2020, Opinion

Biotech capital markets rebounded last year after a down year in 2018. The Nasdaq Biotechnology Index is up 24% for the year, but this is still about 5% below the gains by the rest of the market. Much of these gains are due to the perseverance of a biotech sector that delivered some transformational achievements

Putting patients first and encouraging innovation

January 23, 2019 by Jim Greenwood biotech industry, Biotechnology Innovation Organization, Jim Greenwood Featured Articles, January 7, 2019, Leading Headlines, Pharmacy

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. For much of 2018, capital markets for biotech investment were strong. Some 53 biotech companies went public with more than $5.4 billion in funding, putting the biotech industry on track for the second-best year for IPOs in a decade. And